Quantification of the Carboxylated LGD‐4033 Long‐Term Metabolite in Human Micro‐Dose Excretion Study Urine Samples
Drug Testing and Analysis · 2026
DOI: 10.1002/dta.70130 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Testing and Analysis, 2026. Verfasst von Panagiotis Sakellariou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biochemistry/Center for Preventive Doping Research, German Sport University Cologne, Cologne, Germany. Hauptthemen laut MEDLINE: Pyridines, Substance Abuse Detection. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: World Anti-Doping Agency.
Abstract (Originalsprache)
Selective androgen receptor modulators (SARMs), such as LGD‐4033, are frequently detected in doping control samples and pose significant challenges for result interpretation, particularly at low concentration levels potentially arising from contamination. In this study, a quantitative method for the determination of the carboxylated long‐term metabolite (M5‐b) of LGD‐4033 in human urine was developed and applied to samples obtained from controlled micro‐dose administration studies. Urine samples from single‐ and multiple‐dose administration studies (1, 10, and 50 μg) were analyzed following enzymatic hydrolysis and solid‐phase extraction using LC‐HRMS/MS. Quantification was enabled by the use of a recently synthesized certified reference material, allowing, for the first time, the generation of quantitative excretion data for long‐term metabolite under micro‐dose conditions. The results demonstrated the rapid formation of long‐term metabolite and a clear dose‐dependent increase in urinary concentrations. Extended detection windows were observed for all dosing regimens, with long‐term metabolite remaining detectable for several days after single‐dose administration and for substantially longer periods following consecutive administration (5 days). Accumulation effects during multiple‐dose intake resulted in sustained urinary concentrations and prolonged detectability. The quantitative data generated in this study provide an important basis for improved interpretation of adverse analytical findings involving LGD‐4033 and support a more evidence‐based distinction between different intake scenarios.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biochemistry/Center for Preventive Doping Research, German Sport University Cologne, Cologne, Germany.
- European Monitoring Center for Emerging Doping Agents (EuMoCEDA), Cologne/Bonn, Germany.
ORCID-Profile: Panagiotis Sakellariou, Christian Görgens, Andreas Thomas, Mario Thevis
Förderung
- World Anti-Doping Agency
Zitieren
APA
Sakellariou, P., Schröder, S. M., Thelen, J., Korsmeier, L., Guddat, S., Görgens, C., Thomas, A., & Thevis, M. (2026). Quantification of the Carboxylated LGD‐4033 Long‐Term Metabolite in Human Micro‐Dose Excretion Study Urine Samples. Drug Testing and Analysis. https://doi.org/10.1002/dta.70130
Vancouver
Sakellariou P, Schröder SM, Thelen J, Korsmeier L, Guddat S, Görgens C, et al. Quantification of the Carboxylated LGD‐4033 Long‐Term Metabolite in Human Micro‐Dose Excretion Study Urine Samples. Drug Testing and Analysis. 2026. doi:10.1002/dta.70130
BibTeX
@article{Sakellariou2026,
author = {Sakellariou, Panagiotis and Schröder, Sebastian Marcel and Thelen, Jasmin and Korsmeier, Linus and Guddat, Sven and Görgens, Christian and Thomas, Andreas and Thevis, Mario},
title = {Quantification of the Carboxylated LGD‐4033 Long‐Term Metabolite in Human Micro‐Dose Excretion Study Urine Samples},
journal = {Drug Testing and Analysis},
year = {2026},
doi = {10.1002/dta.70130}
}
EUVIMED